Arca
Skip to content
Tools
Tools

INHBA: Inhibin beta A chain

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. .

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2
  • Type: Protein

Who Is On It, and How Far Along

Every drug ChEMBL records acting on INHBA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Protein or peptide

Approved1

  • Sotatercept

Phase 31

  • Garetosmab

Phase 20

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      SotaterceptApprovedMerck & Co. (MSD)Protein or peptideInhibitorInhibin beta A chain inhibitor23—
      GaretosmabPhase 3RegeneronAntibodyInhibitorInhibin beta A chain inhibitor2—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
      Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial HypertensionSotaterceptPhase 4Not yet recruitingOregon Health and Science University2026-11-16
      A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)SotaterceptPhase 4Not yet recruitingMerck Sharp & Dohme LLC2026-10-28
      A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)SotaterceptPhase 3Not yet recruitingMerck Sharp & Dohme LLC2026-09-24
      Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)SotaterceptNot applicableNot yet recruitingUniversity of Alberta2026-07-14
      A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)SotaterceptPhase 2RecruitingMerck Sharp & Dohme LLC2026-06-15
      A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)SotaterceptPhase 4RecruitingMerck Sharp & Dohme LLC2026-05-22
      A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)GaretosmabPhase 3Not yet recruitingRegeneron Pharmaceuticals2026-04-30
      Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s SyndromeSotaterceptPhase 2Not yet recruitingPhilipps University Marburg2026-03-27
      Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.Sotatercept—Not yet recruitingFranz Rischard, DO2026-03-23
      A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)GaretosmabPhase 3Active, not recruitingRegeneron Pharmaceuticals2022-05-27

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Hypertensive disorder
      0.37
      Ovarian adenocarcinoma
      0.37
      Preeclampsia
      0.36
      Auditory system disorder
      0.28
      Idiopathic generalized epilepsy
      0.27
      Stroke disorder
      0.27
      Hair color
      0.26
      Poisoning
      0.25
      Response to xenobiotic stimulus
      0.25

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3588735, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P08476, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.